The US Food and Drug Administration (FDA) has recently given an in-principle nod for dolutegravir and lamivudine, a two-drug regimen for the treatment of HIV-1 infection. The drug is indicated for patients who have never undergone antiretroviral therapy and don’t have any trace of resistant substances of dolutegravir and lamivudine. The two-drug therapy is the first-ever FDA-approved fixed dose and complete combination therapy for said patients as compared to current standard care therapy which is a three-drug combination.
The new therapy improves the quality of life of patients who are reluctant to take multiple medications for a long period of time, it also eliminates additional toxicity and potential chances of drug-drug interactions. Drug Information: Parameter Dolutegravir Lamivudine General Description HIV-1 integrase inhibitor assisting in blocking strand transfer of the viral…
